The table below shows ImmunityBio, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$75.36M
-$85.91M
-$106.98M
-$84.31M
-$74.93M
-$60.47M
Capital expenditure
$1.78M
$1.12M
$1.26M
$8.43M
$27.35M
$7.08M
Investing cash flow
-$31.65M
$4.13M
-$35.62M
-$8.48M
-$69.31M
$31.84M
Dividends paid
-
-
-
-
IBRX operating cash flow (10-K history)
ImmunityBio, Inc. reported operating cash flow of -$304.94M for fiscal year 2025. That is up 22.1% from -$391.24M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$38.59M (FY 2016) to -$304.94M. Figures come from the company's audited annual reports as filed with the SEC.